Anavex Life Sciences Corp (AVXL)

[camk]

My take is that AD may actually be on the back burner and that their attention has shifted to RHETTS and Parkinsons. Both trials would certainly be HUGELY shorter than the eventual AD trial

I'm all for effectuating the S3 and bringing in approximately $9m. This is very minor dilution and gives them a runway well into next year.

jmho